Feature | March 19, 2012

‘Heartless’ Politician Re-Elected, Performs Duties of Office With Artificial Heart

On Nov. 8, 2011, SynCardia Total Artificial Heart patient Jack Miller became the first politician in the United States to be elected to office without a human heart. On election day, he was able to man the polls and interact with voters using the Freedom portable driver to power his Total Artificial Heart.

SynCardia Total Artificial Heart patient Jack Miller was able to enjoy Christmas

SynCardia Total Artificial Heart patient Jack Miller was able to enjoy Christmas at home last month with his wife Mary Lou and their grandchildren, 8-year-old Emma and 5-year-old Matthew, while waiting for a matching donor heart.

Jack Miller, 62, is probably the only politician in America who smiles when people call him “heartless.” Four months ago, doctors at Virginia Commonwealth University (VCU) Medical Center in Richmond removed his dying heart and replaced it with the SynCardia temporary Total Artificial Heart.

"Golly day, I feel so much better," Miller said, who received his Total Artificial Heart on Sept. 15, 2011. "It's like my body is reawakening for the first time in 11 years. I'm just amazed. No one will ever know how appreciative I am to be able to wait for my heart transplant at home in my community with my family.”

Less than a month after receiving the SynCardia product, Miller was discharged from the hospital using the Freedom portable driver to power his Total Artificial Heart. That same day, he and his wife Mary Lou celebrated their 44th wedding anniversary.

“He is the only boy I ever dated in high school, and I married him soon after we got out of school, and he is my life,” Mary Lou said. “I told one of the nurses one day, if something were to happen to him, you would lose a patient. But if something happens to him, for me, I lose everything.”

On Nov. 1, 2011, Miller was able to return to his position as chairman of the Middlesex County Board of Supervisors and conduct his first meeting with his Total Artificial Heart. Just a week later, Miller was up for re-election.

“I manned the polls on election day and interacted with the voters I represent,” Miller said, who was successfully re-elected to his fifth term in office. “We plugged the Freedom driver into my car’s cigarette lighter and it worked fine. During this whole process, my Freedom driver allowed me to accomplish my goals. It let the citizens know I was up and active and could continue to serve them.”

Miller was first diagnosed with dilated cardiomyopathy 11 years ago. Over the years, his heart continued to weaken, and eventually he was implanted with a defibrillator to shock his heart back into rhythm when it became erratic. After a bad episode of shocks from the defibrillator in September 2011, Mr. Miller’s heart was barely functioning. To save his life, doctors implanted the Total Artificial Heart to bridge him to a heart transplant.

The Freedom driver is CE-approved for use in Europe and undergoing a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical study in the United States. Weighing 13.5 pounds, the Freedom driver is the world’s first wearable power supply for SynCardia’s Total Artificial Heart. It is an investigational device, limited by United States law to investigational use.

SynCardia Systems Inc. is the manufacturer of the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia’s Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 950 implants of the Total Artificial Heart, accounting for more than 230 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

For more information: www.syncardia.com

Related Content

News | Heart Failure| August 28, 2015
August 28, 2015 — BioControl Medical said it has completed enrollment in its INOVATE-HF (INcrease Of VAgal TonE in He
Sunshine Heart, COUNTER HF pivotal study, resumes enrollment, C-Pulse, FDA
News | Heart Failure| August 18, 2015
Sunshine Heart Inc. announced an update in late July on its COUNTER HF U.S. pivotal study for the C-Pulse Heart Assist...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
Mayo Clinic, LVAD, study, heart failure, restrictive cardiomyopathy, RCM

Thoratec HeartMate II image courtesy of Thoratec

News | Ventricular Assist Devices (VAD)| August 07, 2015
Mayo Clinic is announcing results of a study on the effectiveness of left-ventricular assist devices (LVAD) in treating...
FDA, warning, LVADs, left ventricular assist devices, Thoratec, HeartMate II, HeartWare, HVAD
News | Ventricular Assist Devices (VAD)| August 06, 2015
The U.S. Food and Drug Administration (FDA) is alerting healthcare providers, patients and caregivers about serious...
HeartWare, ventricular assist device, HeartWare VAD, recall, update
News | Ventricular Assist Devices (VAD)| August 05, 2015
HeartWare expanded the Class I recall of its ventricular assist device in mid-June due to concerns over damaged or...
LVADs, heart failure patients, echocardiography, ASE, recommendations, guideline
News | Cardiovascular Ultrasound| August 04, 2015
Over the past several years, advanced heart failure patients who have not responded to medical therapy have been given...
Sunshine Heart, C-Pulse, circulatory support system, update
News | Heart Failure| August 03, 2015
Sunshine Heart announced plans to commence a first-in-human study using its novel C-Pulse transcutaneous energy...
MSCs, stem cells, end-stageheart failure, retrograde, coronary sinus,
News | Stem Cell Therapies| July 29, 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus...
heart failure, Adaptive CRT trial, AdaptivCRT algorithm, readmissions
News | Heart Failure| July 22, 2015
Heart failure patients had a significantly lower chance of being readmitted within 30 days of discharge when treated...
Overlay Init